Worth reading
34Immaterial
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 14 May 2026Incoming appointee
2 itemsScheduled Appointment DateEffective 26 June 2026, subject to formal approval at the 141st Annual General Meeting of Shareholders scheduled for 26 June 2026 and at the subsequent meeting of the Board of Directors
Satomi Nobuhiko (里見宣彦)
Previous positionNew appointment
New positionDirectors
Maeda Yuko (前田裕子)
Previous positionNew appointment
New positionOutside directors
Departing officer
2 itemsDate of departure26 June 2026
Fukuda Yasumasa (福田康政)Next role stated
Former PositionDirector, Senior Executive Officer, Head of Pharmaceutical Business, Head of Europe and the Americas
New positionSenior Executive Officer, Head of Europe and the Americas (President of Nihon Parkerizing of America)
Hosogane Hayato (細金逸人)Stepping down
Former PositionDirector (Audit and Supervisory Committee Member)
New positionNot disclosed
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Will not remain on the Board of Directors but will remain as Senior Executive Officer, Will not remain on the Board of Directors
Directors after the change11Number
Shareholders’ meeting approvalRequired. The proposal is believed to concern the election of director candidates, but the formal proposal title in the documents is Not disclosed. The 141st Annual General Meeting of Shareholders is scheduled for 26 June 2026.
| Item | Details |
|---|---|
| Resolution date | 14 May 2026 |
| Scheduled Appointment Date | Effective 26 June 2026, subject to formal approval at the 141st Annual General Meeting of Shareholders scheduled for 26 June 2026 and at the subsequent meeting of the Board of Directors |
| Date of departure | 26 June 2026 |
| Name of appointee | Satomi Nobuhiko (里見宣彦), Maeda Yuko (前田裕子) |
| Appointee's new position | Directors, Outside directors |
| Appointee's previous position | New appointment, New appointment |
| Name of departing officer | Fukuda Yasumasa (福田康政), Hosogane Hayato (細金逸人) |
| Former position of departing officer | Director, Senior Executive Officer, Head of Pharmaceutical Business, Head of Europe and the Americas, Director (Audit and Supervisory Committee Member) |
| New position of departing officer | Senior Executive Officer, Head of Europe and the Americas (President of Nihon Parkerizing of America), Not disclosed |
| Whether the incumbent will remain in office | Will not remain on the Board of Directors but will remain as Senior Executive Officer, Will not remain on the Board of Directors |
| Number of directors after the change | 11 (including 6 outside directors) |
| Subject to Approval by the General Meeting of Shareholders | Required. The proposal is believed to concern the election of director candidates, but the formal proposal title in the documents is Not disclosed. The 141st Annual General Meeting of Shareholders is scheduled for 26 June 2026. |
Items this document does not state (9)
Appointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason for the changes in directors and officers is provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.